iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
August 02 2022 - 7:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients,
today announced that Michel Detheux, PhD, President and Chief
Executive Officer, will participate in a panel discussion at the
upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs
Wide Open – Opportunities and Challenges in Immuno-Oncology” on
Tuesday, August 9, 2022 at 8:00 a.m. ET.
A live webcast of the events will be available on the Investors
section of the company’s website at
https://www.iteostherapeutics.com. An archived replay will be
available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation
immuno-oncology therapeutics for patients. iTeos Therapeutics
leverages its deep understanding of tumor immunology and
immunosuppressive pathways to design novel product candidates with
the potential to fully restore the immune response against cancer.
The Company’s innovative pipeline includes two clinical-stage
programs targeting novel, validated immuno-oncology pathways
designed with optimized pharmacologic properties for improved
clinical outcomes. The first antibody product candidate, EOS-448,
is a high affinity, potent, anti-TIGIT antibody with a functional
Fc domain, designed to enhance the anti-tumor response through a
multifaceted immune modulatory mechanism, currently progressing in
multiple indications in collaboration with GSK. The Company is also
advancing inupadenant, a next-generation adenosine A2A receptor
antagonist tailored to overcome cancer immunosuppression into
proof-of concept trials in several indications following
encouraging single-agent activity in Phase 1. iTeos Therapeutics is
headquartered in Watertown, MA with a research center in Gosselies,
Belgium.
Internet Posting of InformationiTeos routinely
posts information that may be important to investors in the
'Investors' section of its website at www.iteostherapeutics.com.
The company encourages investors and potential investors to consult
our website regularly for important information about iTeos.
For further information, please contact:
Investor Contacts:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contacts:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Apr 2023 to Apr 2024